In her 30 years at SV, Kate’s biotech investments have resulted in the launch of eight drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US.
In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purposed of finding and manufacturing COVID-19 vaccines.
Outside of SV, Kate serves on the Board of the Francis Crick
Institute and ARIA. At weekends Kate spends time in Wales where she
rides horses and mountain bikes, grows vegetables and competes in bog
First class degree, Biochemistry, University of Oxford; MBA, Harvard Business School (Baker Scholar)